Literature DB >> 25550781

Doxycycline attenuates acute lung injury following cardiopulmonary bypass: involvement of matrix metalloproteinases.

Chang-Tian Wang1, Lei Zhang1, Hai-Wei Wu1, Lei Wei1, Biao Xu1, De-Min Li1.   

Abstract

Acute lung injury (ALI) was one of the major complications after cardiopulmonary bypass (CPB). Matrix metalloproteinases (MMPs) play an important role in ALI following CPB. In this study, we investigated the effects of doxycycline (DOX), a potent MMP inhibitor, on MMP-9 and ALI in the rat model of CPB. 48 adult male Sprague-Dawley rats were randomized into four groups: group I (Control group, underwent cannulation + heparinization only); group II (CPB group, underwent 60-minutes of normothermic CPB); group III (Low-dose treatment group, underwent 60-minutes of normothermic CPB with DOX gavage 30 mg/kg ×1 week ahead of CPB); and group IV (High-dose treatment group, underwent 60-minutes of normothermic CPB with DOX gavage 60 mg/kg ×1 week ahead of CPB). The effects of doxycycline on ALI were determined by measuring the lung Wet/Dry ratio, the inflammation of bronchoalveolar lavage fluid (BALF) and the ultrastructural changes of the lungs. The role of doxycycline on MMP-9 was assessed by the plasma concentration, the activity and the expression in lung tissue. Our results demonstrated that the lung Wet/Dry weight ratio and the inflammatory mediators (TNF-α, IL-1β) in BALF were decreased significantly with doxycycline treatment. The lung damages were attenuated by doxycycline. The levels of plasma concentration, the activity and the expression of MMP-9 in lung tissue were suppressed with doxycycline and the effects were dose dependent. Doxycycline could suppress the expression of MMP-9 and cytokines, and improve the ALI following CPB.

Entities:  

Keywords:  Doxycycline; acute lung injury; cardiopulmonary bypass; matrix metalloproteinases-9; rat model

Mesh:

Substances:

Year:  2014        PMID: 25550781      PMCID: PMC4270626     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

Review 1.  Inflammatory response to cardiopulmonary bypass.

Authors:  L H Edmunds
Journal:  Ann Thorac Surg       Date:  1998-11       Impact factor: 4.330

2.  Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass.

Authors:  D E Carney; C J Lutz; A L Picone; L A Gatto; N S Ramamurthy; L M Golub; S R Simon; B Searles; A Paskanik; K Snyder; C Finck; H J Schiller; G F Nieman
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

3.  Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms.

Authors:  J A Curci; D Mao; D G Bohner; B T Allen; B G Rubin; J M Reilly; G A Sicard; R W Thompson
Journal:  J Vasc Surg       Date:  2000-02       Impact factor: 4.268

4.  A rat model of cardiopulmonary bypass with excellent survival.

Authors:  Guo-Hua Dong; Biao Xu; Chang-Tian Wang; Jian-Jun Qian; Hong Liu; Ge Huang; Hua Jing
Journal:  J Surg Res       Date:  2005-02       Impact factor: 2.192

Review 5.  Matrix metalloproteinases: their biological functions and clinical implications.

Authors:  E Hijova
Journal:  Bratisl Lek Listy       Date:  2005       Impact factor: 1.278

6.  Effects of MMP-9 inhibition by doxycycline on proteome of lungs in high tidal volume mechanical ventilation-induced acute lung injury.

Authors:  Adrian Doroszko; Thomas S Hurst; Dorota Polewicz; Jolanta Sawicka; Justyna Fert-Bober; David H Johnson; Grzegorz Sawicki
Journal:  Proteome Sci       Date:  2010-01-29       Impact factor: 2.480

7.  Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats.

Authors:  Jay Steinberg; Jeffrey Halter; Henry J Schiller; Monica Dasilva; Steve Landas; Louis A Gatto; Paivi Maisi; Timo Sorsa; Minna Rajamaki; Hsi-Ming Lee; Gary F Nieman
Journal:  J Surg Res       Date:  2003-05-15       Impact factor: 2.192

Review 8.  Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs.

Authors:  L M Golub; N S Ramamurthy; T F McNamara; R A Greenwald; B R Rifkin
Journal:  Crit Rev Oral Biol Med       Date:  1991

9.  Doxycycline and chloroquine as treatment for chronic Q fever endocarditis.

Authors:  L Calza; L Attard; R Manfredi; F Chiodo
Journal:  J Infect       Date:  2002-08       Impact factor: 6.072

10.  Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model.

Authors:  Chanhung Z Lee; Bin Xu; Tomoki Hashimoto; Charles E McCulloch; Guo-Yuan Yang; William L Young
Journal:  Stroke       Date:  2004-05-27       Impact factor: 7.914

View more
  5 in total

1.  A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats.

Authors:  Shingo Hirao; Hidetoshi Masumoto; Tatsuya Itonaga; Kenji Minatoya
Journal:  J Vis Exp       Date:  2018-03-23       Impact factor: 1.355

Review 2.  Selective toxicity of antibacterial agents-still a valid concept or do we miss chances and ignore risks?

Authors:  Axel Dalhoff
Journal:  Infection       Date:  2020-12-23       Impact factor: 7.455

3.  In Vitro Effects of Doxycycline on Replication of Feline Coronavirus.

Authors:  Magdalena Dunowska; Sayani Ghosh
Journal:  Pathogens       Date:  2021-03-07

Review 4.  Strategies for Pharmacological Organoprotection during Extracorporeal Circulation Targeting Ischemia-Reperfusion Injury.

Authors:  Aida Salameh; Stefan Dhein
Journal:  Front Pharmacol       Date:  2015-12-22       Impact factor: 5.810

Review 5.  Immunomodulation by Tetracyclines in the Critically Ill: An Emerging Treatment Option?

Authors:  Andrea Sauer; Christian Putensen; Christian Bode
Journal:  Crit Care       Date:  2022-03-22       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.